Case Report Open Access
Copyright ©2009 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Mar 14, 2009; 15(10): 1267-1272
Published online Mar 14, 2009. doi: 10.3748/wjg.15.1267
Liver cell adenoma showing sequential alteration of radiological findings suggestive of well-differentiated hepatocellular carcinoma
Takayuki Kogure, Yoshiyuki Ueno, Yuta Wakui, Takao Iwasaki, Tooru Shimosegawa, Division of Gastroenterology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan
Satoshi Sekiguchi, Division of Advanced Surgical Science and Technology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan
Kazuyuki Ishida, Department of Pathology, Tohoku University Hospital, Sendai 980-8574, Japan
Takehiko Igarashi, Division of Gastroenterology Osaki Citizen Hospital, Furukawa 989-6183, Japan
Author contributions: Kogure T, Ueno Y and Wakui Y participated in writing of the manuscript; Kogure T, Ueno Y, Iwasaki T, Shimosegawa T, Sekiguchi S, Ishida K, and Igarashi T participated in treatment of the patient.
Correspondence to: Yoshiyuki Ueno, MD, PhD, Division of Gastroenterology, Graduate School of Medicine, Tohoku University, 1-1 Seiryo, Aoba-ku, Sendai 980-8574, Japan. yueno@mail.tains.tohoku.ac.jp
Telephone: +81-22-7177171
Fax: +81-22-7177177
Received: September 25, 2008
Revised: November 1, 2008
Accepted: November 8, 2008
Published online: March 14, 2009

Abstract

A liver tumor 35 mm in diameter was found incidentally in a 40-year-old woman who had no history of liver diseases or the use of oral contraceptives. Radiological diagnostics showed the typical findings of liver cell adenoma (LCA). Dynamic computed tomography revealed that the tumor showed a homogenous enhancement in the arterial phase and almost the same enhancement as the surrounding liver parenchyma in the delayed phase. The tumor was found to contain fat on magnetic resonance imaging. A benign fat containing liver tumor was suggested. However, radiological findings altered, which caused us to suspect that a well-differentiated hepatocellular carcinoma (HCC) containing fat was becoming dedifferentiated. Partial hepatectomy was performed and the pathological findings showed the typical findings of LCA. This case was an extremely rare LCA, which had no background of risk for LCA and developed the sequential alteration of the radiological findings to suspect well-differentiated HCC.

Key Words: Liver cell adenoma; Hepatocellular carcinoma; Diagnosis; Hepatectomy



INTRODUCTION

Liver cell adenoma (LCA) is a benign tumor of the liver parenchyma that is associated with the use of oral contraceptives or with glycogen-storage disease[1]. The occurrence of LCA in patients without such backgrounds is extremely rare[2]. We report a case of LCA found in a 40-year-old woman without a history of oral contraceptive use in which the sequential alteration of the radiological findings suggested well-differentiated hepatocellular carcinoma (HCC).

CASE REPORT

In November 2006, a 40-year-old woman developed lower abdominal pain and was admitted to a hospital. The patient had no history of liver disease, alcohol consumption, oral contraceptive use, nor the use of any other medication. The family history of the patient was not noteworthy. The patient was diagnosed as having a left tubo-ovarian abscess and tubo-ovariectomy was performed. The resected ovary and oviduct showed the findings of endometriosis with bacterial infection, but there was no indication of neoplastic lesion. At this time, a space-occupying lesion (SOL) 35 mm in diameter was found in the liver by abdominal ultrasonography and computed tomography (CT). In the CT, the lesion in the liver (segment 8) showed slight low density by plain examination and an enhancing effect by the contrast agent. In the magnetic resonance imaging (MRI), the SOL showed almost isointensity on T1 and slightly high intensity on T2 (Figure 1A-B). Superparamagnetic iron-oxide (SPIO)-MRI indicated that the SOL did not show most of the SPIO uptake (Figure 1C). On the gadolinium-enhanced T1, the SOL indicated a slight homogenous enhancement in the arterial phase, and almost the same enhancement as the surrounding liver parenchyma in the delayed phase (Figure 1D-G). The SOL showed almost isointensity on the in-phase-T1 and slightly low intensity on the opposed-phase-T1, which indicated that the SOL contained a fat component (Figure 1H, 1I). A capsule or scars were not detected in the SOL. A benign, fat containing tumor was suggested. The dynamic CT in March 2007 showed that the SOL had not changed in size (Figure 2). The SOL indicated low density by plain examination, showed a slight homogenous enhancing effect in the arterial phase, and, an enhancing effect that was slightly lower than the surrounding liver in the delayed phase (Figure 2). In the dynamic CT after four months, the density of the SOL on plain examination was elevated and the enhancing effect in the arterial phase increased slightly, although the size and the form of the SOL did not show apparent changes (Figure 3). Because of the alteration of the findings in this CT, we suspected that the findings were suggestive of well-differentiated HCC. In August 2007, the patient was referred to our hospital for further examination and treatment. The physical examination of the patient showed no abnormal findings. The blood test indicated no abnormalities including liver related enzymes except slight iron deficiency anemia (Table 1). All the hepatitis virus markers were negative. There were no abnormal findings suggestive of autoimmune liver disease or metabolic liver disease including glycogen-storage disease. Hepatic arteriography was performed and the nodule presented with a slight tumor stain in the arterial phase and the hepatic parenchymal phase, and it did not show an apparent drainage vein (Figure 4). Positron emission tomography showed no difference in accumulation between the nodule and the surrounding hepatic parenchyma and no abnormal accumulation suspicious of malignant tumors in other organs. No abnormal findings were found suggesting a primary tumor in other organs in whole-body CT. Digestive tract endoscopy showed no abnormal findings. Taken together, the above-mentioned findings suggested the possibility that the nodule was a well-differentiated HCC that was dedifferentiating. After receiving informed consent, partial hepatectomy was performed on August 28, 2007.

Table 1 Laboratory data.
IndicatorsValue
White blood cell3980/&mgr;L
Hemoglobin9.8 g/dL
Platelet232 × 103/&mgr;L
Prothrombin time105%
Activated partial thromboplastin time26.7 s
Aspartate aminotransferase17 IU/L
Alanine aminotransferase15 IU/L
Lactate dehydrogenase146 IU/L
Alkaline phosphatase175 IU/L
Gamma glutamyl transpeptidase23 IU/L
Cholinesterase257 IU/L
Total bilirubin0.6 mg/dL
Direct bilirubin0.1 mg/dL
Total protein6.9 g/dL
Albumin4.2 g/dL
Blood urea nitrogen7.5 mg/dL
Creatinine0.6 mg/dL
Uric acid4.0 mg/dL
Na142 mEq/L
K4.2 mEq/L
Cl106 mEq/L
Total cholesterol202 mg/dL
Triglyceride77 mg/dL
Glucose101 mg/dL
C-reactive protein0.03 mg/dL
IgG1157 mg/dL
IgA206 mg/dL
IgM124 mg/dL
HBs-AgNegative
HBs-AbNegative
HCV-AbNegative
α-fetoprotein5.1 ng/mL
Des-γ-carboxy prothrombin34 mAU/mL
Anti-nuclear antibodyNegative
Anti-smooth muscle antibodyNegative
Anti-mitochondrial antibodyNegative
Figure 1
Figure 1 Magnetic resonance imaging (MRI). A: T1; B: T2; C: T2-SPIO; D: Plain; E: Arterial phase; F Portal phase; G: Delayed phase; H: T1 in phase; I: T1 opposed phase.
Figure 2
Figure 2 Computed tomography (CT) in March 2007. A: Plain; B: Arterial phase; C: Portal phase; D: Delayed phase.
Figure 3
Figure 3 CT in July 2007. A: Plain; B: Arterial phase; C: Portal phase; D: Delayed phase.
Figure 4
Figure 4 Digital subtraction angiography (DSA). A: Arterial phase; B: Liver parenchymal phase. Arrow: Tumor stain.

The pathological finding (Figure 5) revealed the following. Hepatocytes more lucent than that of the surrounding hepatic parenchyma had proliferated thickly in the nodule. Hepatocytes did not show severe cellular atypia. Exclusion of the surrounding hepatic parenchyma was apparent, but direct invasion to the surrounding was not seen. The nodule did not contain the portal tracts and bile ducts. Myogenic arteries, large lipid droplets, hemorrhage and degeneration were seen in the nodule. The surrounding hepatic parenchyma had no abnormal findings except fatty change with large lipid droplets around the nodule. Thus, we diagnosed the nodule as a LCA.

Figure 5
Figure 5 Pathological findings. A: Hematoxylin and eosin staining, original magnification, × 50; B: Hematoxylin and eosin staining, original magnification, × 200. Arrow: Myogenic artery.
DISCUSSION

LCA is considered a rare benign tumor of the liver and is distinguished from solitary tumors and adenomatosis[34]. LCA was a very rare tumor until an association with oral contraceptives was reported. Before 1954, only two cases were detected among 5000 autopsies in 36 years[5]. The association with oral contraceptives was thoroughly described in the 1970s[67], and many cases of LCA have been reported since[810].

Due to the progress of diagnostic imaging techniques, the typical findings of LCA have been identified[411]. A typical LCA shows low density or isodensity on plain CT, presents a homogenous contrasting effect on arterial phase and does not show an apparent wash out on delayed phase. A typical LCA in MRI shows almost the same signal intensity as the surrounding parenchyma on T1 and T2 and shows high intensity on fat suppression T2. LCA may often present difficulties in a differential diagnosis with well-differentiated HCC and focal nodular hyperplasia[1214]. The pathological findings of a typical LCA include the following[2101517]: (1) the tumor consists of hepatocytes with almost normal nuclei and cytoplasm presenting a homogenous increase, (2) and does not include the portal area and bile duct, (3) hepatocytes form hepatic cords, but sinusoids are pressed, and hepatic lobule structure is absent, (4) the tumor includes macrovesicular fatty changes, hemorrhage, degeneration, and myogenic arteries.

LCA can be divided into three categories: (1) LCA associated with oral administration of medicines including oral contraceptives and steroids[810], (2) LCA developing as a complication of glycogen-storage diseases[1820], (3) adenomatosis[3415]. Solitary LCAs are most frequently caused by oral contraceptives[721]. The occurrence of adenomatosis is unrelated to the use of oral contraceptives and the frequency of development is not related to sex[15]. It is reported that LCA occurs in patients of glycogen-storage disease type I[19]. In addition to oral contraceptives, oral administrations of such medications as clomiphene[22], barbituric acid[23] or androgen[2425] are reported as risk factors for LCA. Also, it is reported that LCAs associated with oral contraceptives show regression after discontinuing the drug[2627].

The main complications of LCA include tumor hemorrhage and malignant transformation. It is reported that hemorrhage is found in about one half of LCAs and can result in death[91628]. Malignant transformation of LCA is considered to be rare. However, in several reported cases, LCA associated with glycogen-storage diseases and glucocorticosteroids developed HCC[2932]. In another reported case, hepatocarcinogenesis occurred several years after discontinuation of oral contraceptives[32].

Although LCA is a benign liver tumor, treatment is often conducted to avoid hemorrhage and malignant transformation[34]. Surgical treatments such as lobectomy[2133], enucleation[34] and liver transplantation[35] are performed for LCA. Percutaneous ethanol injection[20] and transcatheter arterial embolization[33] are established therapies for low invasive treatment of HCC, and were reported to be performed for LCA. However, precise pathological examination is not possible by these treatments. Since a definitive diagnosis of LCA by diagnostic imaging alone or by needle biopsy is difficult[11], tumor resection is often the most suitable approach. Our case was found by chance during treatment of the endometriosis complicated with bacterial infection. The patient did not have a history of using oral contraceptives or glucocorticosteroids which are known risk factors for LCA. Nor did the patient have metabolic liver disease including glycogen-storage disease. By MRI, the tumor was found to contain fat. In dynamic studies, the tumor showed a homogenous enhancement in the arterial phase and almost the same enhancement as the surrounding liver parenchyma in the delayed phase. These findings were typical for LCA. However, the tumor showed an elevation of the density on plain CT and an increase of the early enhancement in the arterial phase, which caused us to suspect that well-differentiated HCC containing fat was becoming dedifferentiated. Accordingly, hepatic resection was performed.

In a prospective study of 48 LCA cases reported by van der Windt et al[27], serial observation was considered appropriate for tumors with the typical image findings of LCA if the diameter was less than 5 cm. Five of the 48 cases of LCA were resected because the radiological findings changed during serial observations and three of the five cases had well-differentiated HCC, while in the remaining two cases, it was difficult to distinguish between well-differentiated HCC and LCA pathologically. The present case showed the typical radiological findings for LCA and was 35 mm in diameter without an increasing tendency. However, diagnosis only by radiological findings is difficult in patients without a background supporting a diagnosis of LCA such as a history of receiving the above mentioned drugs or glycogen-storage disease. Resection of the tumor in the present case was therefore considered appropriate because of the risk of hemorrhage and possible malignant transformation.

Footnotes

Peer reviewers: Dr. Natalie J Torok, UC Davis Medical Center, Patient Support Services Building, 4150 V Street, Suite 3500, Sacramento, CA 95817, United States; Dr. Serdar Karakose, Professor, Department of Radiology, Meram Medical Faculty, Selcuk University, Konya 42080, Turkey

S- Editor Cheng JX L- Editor O’Neill M E- Editor Yin DH

References
1.  Brophy CM, Bock JF, West AB, McKhann CF. Liver cell adenoma: diagnosis and treatment of a rare hepatic neoplastic process. Am J Gastroenterol. 1989;84:429-432.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Kerlin P, Davis GL, McGill DB, Weiland LH, Adson MA, Sheedy PF 2nd. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology. 1983;84:994-1002.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Chiche L, Dao T, Salamé E, Galais MP, Bouvard N, Schmutz G, Rousselot P, Bioulac-Sage P, Ségol P, Gignoux M. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg. 2000;231:74-81.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Grazioli L, Federle MP, Ichikawa T, Balzano E, Nalesnik M, Madariaga J. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology. 2000;216:395-402.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Edmondson HA. Tumors of the liver and intrahepatic bile ducts. Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology 1958; .  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet. 1973;2:926-929.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med. 1976;294:470-472.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Helling TS, Wood WG. Oral contraceptives and cancer of the liver: a review with two additional cases. Am J Gastroenterol. 1982;77:504-508.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Meissner K. Hemorrhage caused by ruptured liver cell adenoma following long-term oral contraceptives: a case report. Hepatogastroenterology. 1998;45:224-225.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Shortell CK, Schwartz SI. Hepatic adenoma and focal nodular hyperplasia. Surg Gynecol Obstet. 1991;173:426-431.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics. 2001;21:877-892; discussion 892-984.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Charny CK, Jarnagin WR, Schwartz LH, Frommeyer HS, DeMatteo RP, Fong Y, Blumgart LH. Management of 155 patients with benign liver tumours. Br J Surg. 2001;88:808-813.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Herman P, Pugliese V, Machado MA, Montagnini AL, Salem MZ, Bacchella T, D’Albuquerque LA, Saad WA, Machado MC, Pinotti HW. Hepatic adenoma and focal nodular hyperplasia: differential diagnosis and treatment. World J Surg. 2000;24:372-376.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Cherqui D, Rahmouni A, Charlotte F, Boulahdour H, Métreau JM, Meignan M, Fagniez PL, Zafrani ES, Mathieu D, Dhumeaux D. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology. 1995;22:1674-1681.  [PubMed]  [DOI]  [Cited in This Article: ]
15.  Lewin M, Handra-Luca A, Arrivé L, Wendum D, Paradis V, Bridel E, Fléjou JF, Belghiti J, Tubiana JM, Vilgrain V. Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology. 2006;241:433-440.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Erdogan D, Busch OR, van Delden OM, Ten Kate FJ, Gouma DJ, van Gulik TM. Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience. Liver Int. 2006;26:433-438.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Giusti S, Donati F, Paolicchi A, Bartolozzi C. Hepatocellular adenoma: imaging findings and pathological correlation. Dig Liver Dis. 2005;37:200-205.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Fink AS, Appelman HD, Thompson NW. Hemorrhage into a hepatic adenoma and type Ia glycogen storage disease: a case report and review of the literature. Surgery. 1985;97:117-124.  [PubMed]  [DOI]  [Cited in This Article: ]
19.  Parker P, Burr I, Slonim A, Ghishan FK, Greene H. Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy. Gastroenterology. 1981;81:534-536.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Yoshikawa M, Fukui K, Kuriyama S, Tsujimoto T, Nakatani Y, Toyokawa Y, Kurematsu Y, Awata J, Shiroi A, Fukui H. Hepatic adenomas treated with percutaneous ethanol injection in a patient with glycogen storage disease type Ia. J Gastroenterol. 2001;36:52-61.  [PubMed]  [DOI]  [Cited in This Article: ]
21.  Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg. 1988;208:558-564.  [PubMed]  [DOI]  [Cited in This Article: ]
22.  Carrasco D, Barrachina M, Prieto M, Berenguer J. Clomiphene citrate and liver-cell adenoma. N Engl J Med. 1984;310:1120-1121.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Vázquez JJ, Marigil MA. Liver-cell adenoma in an epileptic man on barbiturates. Histol Histopathol. 1989;4:301-303.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Carrasco D, Pallardo L, Prieto M, Moll JL, Cruz JM, Berenguer J. Hepatic adenomata and androgen treatment. Ann Intern Med. 1984;100:316.  [PubMed]  [DOI]  [Cited in This Article: ]
25.  Dourakis SP, Tolis G. Sex hormonal preparations and the liver. Eur J Contracept Reprod Health Care. 1998;3:7-16.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Kawakatsu M, Vilgrain V, Erlinger S, Nahum H. Disappearance of liver cell adenoma: CT and MR imaging. Abdom Imaging. 1997;22:274-276.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  van der Windt DJ, Kok NF, Hussain SM, Zondervan PE, Alwayn IP, de Man RA, IJzermans JN. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg. 2006;93:1495-1502.  [PubMed]  [DOI]  [Cited in This Article: ]
28.  Ameriks JA, Thompson NW, Frey CF, Appelman HD, Walter JF. Hepatic cell adenomas, spontaneous liver rupture, and oral contraceptives. Arch Surg. 1975;110:548-557.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Burri E, Steuerwald M, Cathomas G, Mentha G, Majno P, Rubbia-Brandt L, Meier R. Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. Eur J Gastroenterol Hepatol. 2006;18:437-441.  [PubMed]  [DOI]  [Cited in This Article: ]
30.  Ito M, Sasaki M, Wen CY, Nakashima M, Ueki T, Ishibashi H, Yano M, Kage M, Kojiro M. Liver cell adenoma with malignant transformation: a case report. World J Gastroenterol. 2003;9:2379-2381.  [PubMed]  [DOI]  [Cited in This Article: ]
31.  Uto H, Shigehira M, Kawano T, Nagatomo H, Kuribayashi T, Taniguchi S, Koga K, Komada N, Kitamura T, Maruyama T. Liver cell adenoma in a young man with elevated serum PIVKA-II level. J Gastroenterol. 1996;31:441-445.  [PubMed]  [DOI]  [Cited in This Article: ]
32.  Gordon SC, Reddy KR, Livingstone AS, Jeffers LJ, Schiff ER. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med. 1986;105:547-549.  [PubMed]  [DOI]  [Cited in This Article: ]
33.  Ribeiro A, Burgart LJ, Nagorney DM, Gores GJ. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg. 1998;4:388-398.  [PubMed]  [DOI]  [Cited in This Article: ]
34.  Flejou JF, Barge J, Menu Y, Degott C, Bismuth H, Potet F, Benhamou JP. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology. 1985;89:1132-1138.  [PubMed]  [DOI]  [Cited in This Article: ]
35.  Mueller J, Keeffe EB, Esquivel CO. Liver transplantation for treatment of giant hepatocellular adenomas. Liver Transpl Surg. 1995;1:99-102.  [PubMed]  [DOI]  [Cited in This Article: ]